Technical Data
A2299-99P
APRIL, ED2, Blocking Peptide (a Proliferation Inducing Ligand, TALL-2, TNF and ApoL-related Leukocyte-expressed Ligand 2, TRDL-1a, TNF-related Death Ligand 1a, TNFSF13)
50ug
|
Technical Data |
|
A2299-99P |
APRIL, ED2, Blocking Peptide (a Proliferation Inducing Ligand, TALL-2, TNF and ApoL-related Leukocyte-expressed Ligand 2, TRDL-1a, TNF-related Death Ligand 1a, TNFSF13) |
50ug |
| Molecular Biology | Storage: -20°CShipping: Blue Ice |
|
Synthetic peptide (CIRSMPSHPDRAYNS) corresponding to amino acids 196 to 210 of human APRIL (1-3). Members in the TNF superfamily regulate immune responses and induce apoptosis. A novel member in the TNF family was recently identi ed by several groups and designated APRIL (for a proliferation-inducing ligand), TALL-2 (for TNF-and ApoL-related Leukocyte-expressed Ligand 2), and TRDL-1a (for TNF related death ligand 1a) in human and mouse (1-4). Two receptors for APRIL were recently identi ed and designated TACI and BCMA (5-7). APRIL stimulates B and T cell proliferation, triggers humoral immune responses, activates NF-kB, and induces cell death (1-7). APRIL and its close relative of BlyS and their receptors BCMA and TACI are involved in diseases of autoimmunity and cancer (8,9). Applications: Suitable for use in ELISA and Western Blot. Other applications not tested. Storage and Stability: Lyophilized powder may be stored at -20°C. Reconstitute to nominal volume by adding sterile 25% glycerol and store at -20°C. May be stored at 4°C for short-term only. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. |
Source: Synthetic peptide Purity: Purified 60-70% Concentration: ~0.2mg/ml Form: Supplied as a lyophilized powder. Intended for research use only, not for use in human, therapeutic or diagnostic applications. |
|
1. Hahne M, Kataoka T, Schroter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998;188(6):1185–90. 2. Shu HB, Hu WH, Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol. 1999;65(5):680–3. 3. Kelly K, Manos E, Jensen G, et al. APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death. Cancer Res. 2000;60(4):1021–7. 4. Yu G, Boone T, Delaney J, et al. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol. 2000;1(3):252–6. 5. Wu Y, Bressette D, Carrell JA, et a. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high af nity receptor for TNF family members APRIL and BLyS. J Biol Chem. 2000;275(45):35478–85. 6. Marsters SA, Yan M, Pitti RM, et al. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol. 2000;10(13):785–8. 7. Rennert P, Schneider P, Cachero TG, at al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med. 2000;192(11):1677–84. 8. Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000;404:995–9 9. Ware CF. APRIL and BAFF connect autoimmunity and cancer. J Exp Med. 2000;192(11):F35–8.
|
||